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Judith A. Shizuru, Deepta Bhattacharya, Marina Cavazzana-CalvoAt the most basic level, success of an allogeneic hematopoietic cell transplantation (HCT) procedure relies
upon the engraftment of recipients with donor hematopoietic stem cells (HSCs) that will generate blood
formation for the life of that individual. The formula to achieve durable HSC engraftment involves multiple
factors including the recipient conditioning regimen, the nature of the genetic disparity between donor and
recipient, and the content of the hematopoietic graft. Animal and clinical studies have shown that the biology
of host resistance is complex, involving both immune and nonimmune elements. In this article, we review the
factors that contribute to host resistance, describe emerging concepts on the basic biology of resistance, and
discuss hematopoietic resistance as it relates specifically to patients with severe combined immunodefi-
ciencies (SCID)— disorders that bring unique insights into the dynamics of cell replacement by allogeneic
HSCs and progenitor cells.
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CONSTITUTE THE ENGRAFTING
POPULATION
Hematopoietic grafts are composed of mixtures
of cells at different stages of development. Con-
tained within these grafts are rare populations of
hematopoietic stem cells (HSCs) that constitute
\0.1% of the total cells [1]. Because HSCs are the
only cells capable of self-renewal and of giving rise
to all blood cell lineages, they are the only cells
that must engraft in transplant recipients to achieve
true durable hematopoiesis. Under conditions of
normal hematopoiesis adult HSC reside in a special-
ized microenvironment or niche within the bone
marrow (BM), which provides the necessary factors
and molecular cues to maintain the cycle of self-
renewal, proliferation, and differentiation [2].
Thus, engraftment is only achieved when the do-
nated HSCs traverse the peripheral circulation and
tissues and find their way to marrow niche where
they settle to productively resume the task of blood
formation.Stanford University, Stanford, california.
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Immune-mediated resistance is the first hurdle
that an incoming HSC must overcome on its journey
to the BM. The surface molecules expressed by an
HSC determine which element of host immunity can
target and eliminate these cells. Although largely un-
appreciated as a population that can confer resistance,
macrophages and other phagocytic cells of the reticu-
loendothelial system (RES) are a first line of defense in
clearing cells from the blood stream. A recent report
[3] suggests that CD47 expression confers protection
of HSC from macrophage killing. CD47 is an immu-
noglobulin-like cell surface protein expressed on
a wide range of blood cells, including HSC. CD47 in-
teracts with its receptor on macrophages, SIRPa, in-
hibiting phagocytosis of healthy cells. It was shown
that mobilizing cytokines and inflammatory stimuli in-
duce the transient upregulation of CD47 expression on
mouse HSCs and progenitors just prior to and during
their migratory phase. Furthermore, the level of CD47
on these cells determined the probability that the HSC
would be engulfed in vivo. This mechanism of macro-
phage evasion byCD47 expression appears to be a gen-
eral strategy applicable to either autologous or
allogeneic HSC. The role of host phagocytic cells as
specifically applied to allograft resistance is largely un-
explored.
Beyond the RES, T lymphocytes and natural killer
(NK) cells are the primary immune mediators of allo-
geneic HSC resistance [1]. When transplant pairs are
fully matched at the major histocompatibility complex
(MHC) loci, that is, in humans the HLA-encoded
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recipient, T cell immunity predominates. However,
if HLA disparities exist, the most extreme example
being haplo-identical transplantations, NK cells also
play an important role. The prominent role of NK
cells in HSC resistance is unique to the hematopoietic
system, as NK cells do not appear to participate signif-
icantly in the rejection of solid organs. The differential
effect of T versus NK cells on resisting hematopoietic
grafts in the setting of the distinct genetic combina-
tions is underscored by the observations made in
patients with severe combined immunodeficiencies
(SCID). The SCID syndrome is variable with regard
to the lymphocyte defects. SCID recipients that lack
both T and NK cells engraft more readily when
HLA-incompatible donors are utilized compared to
those that have T cell defects only; and overall, the for-
mer have significantly better outcomes than patients
with functional NK cells [4].
Although it is acknowledged that T and NK cells
are responsible for immune resistance, precise delinea-
tion of their antigenic targets andmechanism(s) of how
donor HSC are eliminated is incomplete. Via their
antigen specific T cell receptor (TCR), T cells recog-
nize and respond to minor antigens presented as pep-
tides bound to MHC molecules, and respond even
more vigorously to foreignMHCmolecules. Presenta-
tion of these alloantigens can be carried out by antigen
presenting cells (APCs) derived from either donor or
host. Control of NK reactivity is distinctly different
from T cells. Unlike T cells, NK cells possess an array
of surface molecules, rather than a single dominant
one, which are either MHC class I specific or non-
MHC class I specific. Engagement of these receptors
can result in NK cell activation or inhibition. Because
NK cells are known to respond strongly to cells that do
not express self-MHC molecules, one hypothesis
based on the pattern of NK reactivity observed in
experimental models, is that NK cells destroy MHC-
disparate HSCs if the HSC targets do not express
the MHC-alleles that would inhibit an NK clone’s
activity.
Whether or not the initial antigen presentation
events trigger downstream aggressive inflammatory
and cytotoxic activities, which result in elimination
of the donor cells, is determined by the cytokine milieu
in which the antigen interaction takes place and, in the
case of T cells, the costimulatory signals provided by
the APCs. Animal studies suggest that multiple cell
and effector pathways are capable of causing the ulti-
mate abolishment of donor HSC [5]. CD41 and
CD81 T cells, together or separately, as well as NK
cells have been demonstrated as the chief cause of
engraftment resistance in different animal models. In
addition to the type of genetic disparity between donor
and recipient, and the type of conditioning regimen
employed (myeloablative [MA] or nonmyeloablative[NMA]), the recipient’s state of antigen exposure is an-
other factor in determining which host effector T cell
subpopulation will dominate. Not surprisingly, pa-
tients unintentionally sensitized (i.e., aplastic anemia
[AA] [6]) or experimental animal recipients intention-
ally sensitized to donor antigens demonstrate stronger
barriers to engraftment compared with recipients who
are naive with respect to donor antigens [5]. Mouse
models that are MHC-matched primed against recip-
ient antigens to induce memory T cells have been
shown to resist hematopoietic allogeneic grafts with
enhanced kinetics compared with unsensitized recipi-
ents [5].
To date, no single cytotoxic pathway has been
identified as the primary mechanism of donor cell
clearance. Studies by us [7] and others [5] have shown
that recipient mice genetically deficient in components
of the major cytotoxicity pathways (perforin, FasL,
granzyme B) or multiple cytokines show little to no
diminution in the ability to eliminate allogeneic hema-
topoietic cells. These negative studies direct attention
to nonspecific pathways of inflammation as key effector
components of the engraftment barrier. There is grow-
ing appreciation of the cellular dynamics that occurs
during the process of engraftment between ‘‘conven-
tional’’ T cells that mediate pro-cytotoxic and inflam-
matory activity and the effects of regulatory cells cells
onmodulating this alloreactivity.CD41CD251FoxP31
(Treg) cells derived from either host or donor have
been shown to assist in the engraftment of allogeneic
hematopoietic cells [8-11]. Because there appears to
be little downside to exploiting the activities of Tregs,
it is anticipated that the use of this population for
engraftment facilitation (and for the amelioration of
graft-versus-host disease [GVHD]) will be rapidly
translated to clinical trials.NICHE SPACE
Host immunity is generally thought to constitute
the largest barrier toHSC engraftment. However, suc-
cessful engraftment is critically dependent upon HSCs
making their way to the correct microenvironment and
establishing a foothold in that milieu. The notion that
BM ‘‘space’’ must be created by cytoreductive agents or
radiation to accommodate transplanted HSC was first
proposed over 30 years ago [12]. This hypothesis is
based on the concept that HSC numbers and behavior
are regulated by physically discrete locations or niches
within the BM. Experimental studies by us [13,14] and
others [15] have led to the conclusion that space in this
regard is occupation of the niche by host resident
HSC, and unless these cells are unseated, donor en-
graftment will not take place. Although the precise
identities of the niche cells are still largely unknown
and controversial [16,17], a large amount of data
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through the use of specific adhesion molecules and
chemokine gradients [2]. Through these interactions,
HSCs can be assured of receiving the appropriate sup-
portive signals that allow them to retain their stem cell
identity.
Counterbalanced against these studies are data
suggesting that recipient BM cells can be readily dis-
placed by syngeneic transplanted BM in an efficient
and linear dose-dependent manner, even in the ab-
sence of conditioning [18,19]. Although these studies
did not directly assess HSC replacement, the data
were interpreted as more consistent with a model
wherein HSCs do not reside locked into fixed loca-
tions in the BM, but instead receive their regulatory
signals through limiting quantities of freely diffusible
factors. To clarify these divergent views, we and
others performed studies to test the ease by which
host HSCs can be replaced by purified HSCs, rather
than simply total marrow replacement [13-15,20].
Unfractionated BM is known to contain a number
of different cell types that have been reported to influ-
ence engraftment and replacement (see next section),
such as host-reactive T cells and stromal cells [21-23].
We found using purified HSC innocula that a low
level of HSC replacement does indeed occur in nor-
mal mice, even in the absence of cytoreductive condi-
tioning, but not to the degree previously reported.
A number of studies have shown that HSCs and/or
progenitor cells circulate under physiologic conditions
[24-26]. Thus, we hypothesized that the low level
of HSC engraftment reflects a steady-state egress of
HSCs from their niches allowing engraftment of
donor HSCs. In this model, transplanted HSCs do
not directly displace host HSCs that are stable residing
within the niche, but engraft only in niches that had
been vacated through the physiologic egress of host
HSCs. By cell surface phenotype and transplantation
of unfractionated blood, it was determined that a calcu-
lated 1% to 5% of the total pool of HSCs enter into
the circulation of mice each day. Bromodeoxyuridine
(BrdU) feeding experiments showed that HSCs in
the peripheral blood (PB) incorporate BrdU at the
same rate as do HSCs in the marrow, suggesting that
egress from the marrow to the blood can occur with-
out cell division and can leave behind vacant HSC
niches. To test the hypothesis that small numbers of
niches are continuously vacated, repetitive daily trans-
plantations of small numbers of HSCs were performed
over the course of 7 days. This approach led to signif-
icantly higher levels of engraftment than did large
single bolus transplantation of the same numbers of
HSCs [27]. Thus, these data provide insight as to
howHSC replacement can occur despite the residence
of endogenous HSCs in niches, and further suggest
therapeutic interventions that capitalize upon physio-
logic HSC egress.To further demonstrate that transplanted HSCs
are limited by occupancy of appropriate niches by
endogenous HSCs, an antibody-based approach was
developed to eliminate host HSCs prior to transplan-
tation [20]. Administration of ACK2, an antibody
that blocks c-Kit function, led to the transient removal
of .98% of endogenous HSCs in immune-deficient
mice. Subsequent transplantation of these mice with
donor HSCs led to chimerism levels up to 90%,
whereas transplantation of mice without precondition-
ing led to engraftment levels of at most 3%. Further
support of the concept that the space limitations in
the marrow result from endogenous HSCs that hold
tenure within the niche, come from studies using the
pharmacologic agent AMD3100, a CXCR4 inhibitor.
AMD3100 rapidly induces the egress of HSCs out of
the marrow, and has been shown to improve the levels
of donor HSC engraftment relative to untreated recip-
ients [28]. It is anticipated that these types of specific
approaches that facilitate the creation of HSC niche
space while avoiding DNA damage and other toxicities
will be incorporated as part of the conditioning regi-
mens of the future.NON-HSC CELLS IN A GRAFT FACILITATE
HSC ENGRAFTMENT
Although host-versus-graft (HVG) responses and
endogenous HSC in recipients present the barrier to
incoming donor cells, an unmanipulated hematopoi-
etic graft carries its own cellular armamentarium capa-
ble of lowering engraftment resistance. The concept
that immune cells contained in an allograft aid in
HSC engraftment arose from studies in patients. Fol-
lowing the determination that T cells are the primary
mediators of GVHD, strategies to purge BM cells of
T cells were applied to clinical protocols [29,30]. Un-
fortunately, purging of graft T cells resulted in in-
creased engraftment failures along with significantly
increased deaths from this complication [29,30]. These
results are one reason why T cell depletion is not rou-
tinely performed for HLA-identical grafts. Animal
studies using T cell-depleted grafts confirmed the phe-
nomenon of engraftment failure [31] and mouse
models have been utilized to identify and characterize
the role of facilitating cells in marrow engraftment.
Several groups [32-35] have identified non-HSC pop-
ulations that express the CD8molecule as able to facil-
itate allogeneic HSC engraftment across MHC
barriers. Interestingly, some of these studies suggest
that both CD81 conventional T cells (CD8a1TCR1)
and a non-T cell population(s) (CD8a1TCR2) func-
tion to enhance engraftment. In a model wherein ani-
mals received purified HSC cotransplanted with
facilitating populations it was observed that grafts of
HSC plus CD81TCR1 cells led to significantly higher
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that received HSC alone or HSC plus the
CD81TCR2 population, suggesting that one mecha-
nism by which the former group facilitates HSC
engraftment is by clearing host immune cell popula-
tions that confer resistance [33]. That CD81TCR1
cells also target host HSC is an important corollary
to these findings, but has not yet been definitely
proven.
The increasing evidence that nonspecific inflam-
mation is a cause of allograft resistance suggests
that more than one mechanism of facilitation exists.
In support of this idea are reports that cotransplanta-
tion of donor Treg cells facilitate engraftment
[8,9,11]. On the flip side, but further reinforcing
the effect of donor cells on host responses, are the
studies showing that allogeneic marrow engraftment
is retarded if recipients are treated with agents
(i.e., cytosine–phosphorothioate–guanine oligodeoxy-
nucleotides [CpG ODNs]) that bind to Toll-like
receptors (TLRs) and trigger innate immune cell
activation [36]. TLR agonists induce the expression
of costimulatory molecules and multiple chemokines
and cytokines. Interestingly, these studies revealed
an unexpected outcome that donor APCs and not
host cells activated by TLR9 agonists CpG ODNs
promoted BM rejection. Thus, donor and host may
be differentially affected by activating signals, under-
scoring the complex dynamics that occur following
an allograft infusion. Future directions for study in-
clude the details of the location, timing, and regula-
tion of these cellular events.CLINICAL LESSONS ON
ENGRAFTMENT—SCID
SCID comprises a number of rare monogenic dis-
orders with the common characteristic of blocking T
cell differentiation and direct impairment of B cell
immunity. Some forms of SCID also lack NK cells.
The molecular defects that underlie SCID include
more than 14 distinct genetic variants. Four main
mechanisms have been described for the pathophysiol-
ogy: (1) premature cell death caused by accumulation
of purine metabolites, as seen in adenosine deaminase
(ADA) deficiency; (2) defective cytokine-dependent
survival signaling in T cell precursors; (3) defective
V(D)J rearrangement of the TCR and B cell receptor
genes; and (4) defective pre-TCR and TCR signaling.
The clinical presentation of the different SCID condi-
tions is fairly uniform and characterized by the early
onset of life-threatening infections. The severity of
these clinical manifestations makes SCID a medical
emergency that, in the absence of treatment, leads to
death within the first year of life. Although subsets of
SCID patients can benefit from enzyme replacement(ADA type) or gene therapy, at present the only known
cure for most children with SCID is allogeneic HCT.
Because SCID patients demonstrate profound
defects in T cell and/or NK immunity-the known
mediators of allogeneic hematopoietic cell resistance,
transplantation of these children provides unique
insight into immune resistance and these patients are
considered appropriate for protocols using haploident-
ical grafts. Clinical experience shows that the optimal
donor is an HLA-matched sibling or parent. However,
haploidentical parental transplantations are often per-
formed, as most children do not have such an HLA-
matched relative available and because of the length
of time needed to identify an unrelated donor. Studies
performed over the years comparing SCID recipients
of haploidentical, T cell-depleted grafts with those
that undergo transplantation from an HLA-identical
donor unfortunately show that overall survival (OS)
is uniformly poorer in the former patient group
[37,38], with the principle obstacles being graft failure
or graft loss, GVHD, and a delayed time course to T
cell development. Furthermore, for patients with func-
tional NK cells, HLA differences between donor and
recipient increase the risk of graft failure and poor out-
come. Clinical studies have consistently reported that
long-term survival of NK1 SCID patients is roughly
half that of the NK2 SCID patients [4].THE NEED FOR NICHES
Children with SCID have been shown to benefit
from the infusion of allogeneic cells without condi-
tioning. However, whether or not SCID patients
should receive conditioning and what type should be
administered is controversial. Certain forms of
SCID, that is, those forms arising from mutations in
DNA repaired genes, show increased sensitivity to
ionizing radiation and alkylating agents—a major
concern when considering transplant conditioning.
Although children that receive no conditioning experi-
ence less upfront toxicity and demonstrate functional
T cell immunity provided by donor cells, many dem-
onstrate delayed or absent B cell recovery, and in gen-
eral, myeloid and erythroid cells remain of recipient
origin. Thus, in the absence of conditioning, either
no or very low level true HSC engraftment occurs,
again pinpointing the importance of emptying niche
space that is the presumed effect of conditioning. As
a further impetus to achieve HSC engraftment, we
found that patients that are unconditioned or that re-
ceive reduced-intensity conditioning (RIC) demon-
strate very low levels of new T cell production by 10
years after transplantation [39].
Approaches to create HSC niche space with lim-
ited morbidity are currently under development.
Recently, the validity of targeted therapy using
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immunodeficiency that were conditioned with a novel
minimal-intensity conditioning (MIC) regimen con-
sisting of two rat anti-CD45 monoclonal antibodies
(mAbs) [40]. Fifteen of 16 patients engrafted, and 11
of these patients achieved full or high levels of mixed
chimerism in both lymphoid and myeloid lineages.
Another promising strategy in this regard is the anti-
c-Kit antibody used in immunodeficient mice [20]
(discussed above), which permitted high levels of
engraftment of donor HSC without additional condi-
tioning. For NK1 SCID patients, such an approach
could be partnered with antibodies that target NK cells
specifically.
In both experimental animal models and in clinical
transplantation, the SCID defects have been particu-
larly instructive on highlighting the importance of
niche space that exists at all levels of hematopoietic
development. Several studies show that defects in
immune-deficient animals are more easily corrected
by donor cells if there is niche availability at specific
stages of lymphocyte development. Perhaps the best
examples are Rag-1-deficient mice, which exhibit
high numbers of double-negative (DN2/DN3) thymic
cells. These mice are refractory to thymic reconstitu-
tion following HCT in the absence of conditioning
because of competition for thymic niche seeding. In
contrast, gc-deficient mice in which DN T cells can-
not proliferate, are well reconstituted [15]. Our labora-
tory reported similar results [41] for B lineage cells,
indicating that the efficiency of B cell reconstitution
in mice after nonconditioned HCT depends on the
available of niches/resources in the BM environment.
This study compared transplants in unconditioned
mice that were severely deficient in B cell precursors
in the BM (Rag-1gc or FLT3 IL-7Ra double knock-
out mice) with B cell-deficient animals that contain
normal numbers of pro-B cells (Rag22/2 or Rag2
IL-2Rb double knockout mice). B-cell reconstitution
was limited in recipient mice containing a normal
pro-B cell pool, whereas immature and mature B cell
numbers reached wild-type levels in mice with com-
promised early B cell precursors. This idea of opportu-
nistic expansion of progenitors in a permissive niche
environment has been borne out in patients wherein
superior T cell reconstitution was observed in SCID
patients with the gc defect [39].PERSISTENT IMMUNE DEFICIENCYAND
STRATGIES FOR THE FUTURE
A key obstacle that persists in haploidentical HCT
is the severe, long-lasting immunodeficiency that fol-
lows infusion of CD34 selected cells—a condition
that is sometimes worsened by the occurrence of acute
or chronic GVHD (aGVHD, cGVHD). Thus,although engraftment is achieved, it is as yet unclear
why neothymopoiesis is markedly delayed (6-12
months in pediatric patients). The consequences of
this long-lasting immunodeficiency are opportunistic
viral infections that account for30% ofmortality ob-
served in patients receiving an allograft from HLA-
partially incompatible donors [38,42]. To reduce the
frequency of these complications, several adoptive
immunotherapy strategies have been or are being
tested in the clinic. The basic idea is to provide the re-
cipient with either mature T cells devoid of specific,
antihost alloreactivity or pathogen-specific mature do-
nor cells. One limitation of pathogen-specific immu-
notherapy is that the monospecificity of the sorted T
cells will be a limitation in multi-infected patients.
Other feasible approaches include the use of Notch li-
gands to preferentially expand lymphoid progenitors.
Additional strategies known to be effective in mouse
models and in clinical trials include the use of thymo-
protective agents (e.g., keratinocyte growth factor) or
thymopoietic factors (e.g., androgen ablation using
lenprolide, IL-7 administration and growth hormone
administration). These strategies have been, and will
continue to be, translated into clinical trials in the
near future. In parallel with these transplantation stud-
ies are the development of gene therapies, which may
become important alternatives when faced with very
young, severely affected patients who lack an HLA-
compatible donor [43].ACKNOWLEDGMENTS
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